Biophytis announces the temporary suspension of the trading of its shares

Communiqué de presse

Biophytis announces the temporary  suspension of the trading of its shares

Paris (France) and Cambridge (Massachusetts, USA), June 19, 2025 – 11:00 PM (CET) – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases announces the temporary suspension of the trading of its shares by Euronext, due to the non-publication of its annual financial report for the fiscal year ended December 31, 2024. The report will be published following certification of the accounts by the statutory auditors, which is expected by the end of June 2025.

Trading of Biophytis shares on Euronext Growth Paris was suspended on June 17, 2025, and is expected to resume after the publication of the annual financial report. The Company will keep the market informed of the date on which trading will resume.

***

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com. 

Disclaimer

This press release contains forward-looking statements.  Forward-looking statements include all statements that are not historical facts.  In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable.  However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company’s 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether because of new information or otherwise, except as required by law.

                                                                                                                                                                1

Biophytis Contacts

Investor Relations

Investors@biophytis.com

US Investors Pascal Nigen – Alpha Bronze pnigen@alphabronzellc.com Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27

Media contacts

Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78

                                                                                                                                                                2